{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:44:32Z","timestamp":1790232272202,"version":"4.1.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Among patients with breast cancer, inconsistent findings have been published on racial disparities in achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT).<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether racial disparities exist in achieving pCR and what factors contribute to them.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Within the ongoing Chicago Multiethnic Epidemiologic Breast Cancer Cohort (ChiMEC), which consists of a prospectively ascertained cohort of patients with breast cancer, 690 patients with stage I to III breast cancer receiving NACT were identified for this single-institution study at the University of Chicago Medicine. Patients diagnosed between 2002 and 2020 (median follow-up: 5.4 years) were included; next-generation sequencing data on tumor-normal tissue pairs were available from 186 ChiMEC patients, including both primary and residual tumor samples. Statistical analysis was performed from September 2021 to September 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Demographic, biological, and treatment factors that could contribute to disparities in achieving pCR.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>pCR was defined as the absence of invasive cancer in the breast and axillary nodes, irrespective of ductal carcinoma in situ.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 690 patients with breast cancer, with a mean (SD) age of 50.1 (12.8) years. Among the 355 White patients, 130 (36.6%) achieved pCR compared to 77 of the 269 Black patients (28.6%;P<\/jats:italic>\u2009=\u2009.04). Not achieving pCR was associated with significantly worse overall survival (adjusted hazard ratio, 6.10; 95% CI, 2.80-13.32). Black patients had significantly lower odds of achieving pCR compared with White patients in the hormone receptor\u2013negative\/ERBB2<\/jats:italic>+ subtype (adjusted odds ratio, 0.30; 95% CI, 0.11-0.81). Compared with White patients withERBB2<\/jats:italic>+ disease, Black patients were more likely to have MAPK pathway alterations (30.0% [6 of 20] vs 4.6% [1 of 22];P<\/jats:italic>\u2009=\u2009.04), a potential mechanism of anti-ERBB2<\/jats:italic>therapy resistance. Tumor mutational burden and somatic alterations in several genes (eg,FGF4<\/jats:italic>,FGF3, CCND1, MCL1, FAT1, ERCC3, PTEN<\/jats:italic>) were significantly different between the primary and residual tumors.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with breast cancer, racial disparities in response to NACT were associated with disparities in survival and varied across different breast cancer subtypes. This study highlights the potential benefits of better understanding the biology of primary and residual tumors.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.3329","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:14:11Z","timestamp":1680189251000},"page":"e233329","source":"Crossref","is-referenced-by-count":32,"title":["Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Fangyuan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan"},{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Howard","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiyana","family":"Kaneva","sequence":"additional","affiliation":[{"name":"Tempus Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jones","sequence":"additional","affiliation":[{"name":"Tempus Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S. K.","family":"Bell","sequence":"additional","affiliation":[{"name":"Tempus Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Jaskowiak","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezheng","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"},{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"zoi230131r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100985","article-title":"Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns.","volume":"38","author":"Lima","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"3","key":"zoi230131r2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi230131r3","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1038\/s41467-021-27079-w","article-title":"Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes.","volume":"12","author":"Ansari-Pour","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"zoi230131r4","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/jamaoncol.2017.0595","article-title":"Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas.","volume":"3","author":"Huo","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi230131r5","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1038\/s41467-018-06616-0","article-title":"Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.","volume":"9","author":"Pitt","year":"2018","journal-title":"Nat Commun"},{"issue":"1A","key":"zoi230131r6","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.","volume":"19","author":"Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"zoi230131r7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies.","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"zoi230131r8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"51","key":"zoi230131r9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jncimonographs\/lgv004","article-title":"Neoadjuvant chemotherapy: what are the benefits for the patient and for the investigator?","volume":"2015","author":"Hayes","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"zoi230131r10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12885-019-5499-2","article-title":"Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.","volume":"19","author":"Klein","year":"2019","journal-title":"BMC Cancer"},{"issue":"9938","key":"zoi230131r11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"zoi230131r12","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1002\/cncr.25296","article-title":"Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race\/ethnicity.","volume":"116","author":"Chavez-Macgregor","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"zoi230131r13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-015-3350-2","article-title":"Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.","volume":"150","author":"Tichy","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"zoi230131r14","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.2015.63.7801","article-title":"Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Data Base.","volume":"33","author":"Killelea","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi230131r15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial.","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi230131r16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi230131r17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10549-020-05984-w","article-title":"Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.","volume":"185","author":"Zhao","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi230131r18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13058-021-01397-9","article-title":"Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.","volume":"23","author":"Shang","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"8","key":"zoi230131r19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi230131r20","first-page":"3545","article-title":"Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer.","volume":"50","author":"McClelland","year":"1990","journal-title":"Cancer Res"},{"issue":"8","key":"zoi230131r21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi230131r22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi230131r23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2105\/AJPH.73.11.1247","article-title":"The National Death Index.","volume":"73","author":"MacMahon","year":"1983","journal-title":"Am J Public Health"},{"issue":"24","key":"zoi230131r24","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.v10i24","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"zoi230131r25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations.","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"issue":"2","key":"zoi230131r26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas.","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"zoi230131r27","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2?+?breast cancers evade anti-HER2 therapy via a switch in driver pathway.","volume":"12","author":"Smith","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"zoi230131r28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jamaoncol.2015.3856","article-title":"Delayed initiation of adjuvant chemotherapy among patients with breast cancer.","volume":"2","author":"Chavez-MacGregor","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi230131r29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"time to surgery and breast cancer survival in the United States.","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"18","key":"zoi230131r30","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi230131r31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy.","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"zoi230131r32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity.","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"zoi230131r33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-020-05599-1","article-title":"Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2\/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).","volume":"181","author":"Greenwell","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi230131r34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.5834","article-title":"Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US.","volume":"6","author":"Shubeck","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230131r35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy.","volume":"7","author":"Dieci","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"zoi230131r36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ajcp\/aqy028","article-title":"Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease?","volume":"150","author":"Landmann","year":"2018","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"zoi230131r37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial.","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi230131r38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","article-title":"Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.","volume":"140","author":"Lips","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi230131r39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-020-05607-4","article-title":"Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.","volume":"181","author":"Purrington","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"zoi230131r40","doi-asserted-by":"publisher","first-page":"e788","DOI":"10.1016\/j.clbc.2022.07.001","article-title":"Characterizing clinicopathologic features of estrogen receptor-positive\/progesterone receptor-negative breast cancers.","volume":"22","author":"Fei","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"zoi230131r41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-018-0939-5","article-title":"Frequency of breast cancer subtypes among African American women in the AMBER consortium.","volume":"20","author":"Allott","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"10","key":"zoi230131r42","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/cac2.v41.10","article-title":"Estrogen receptor-low breast cancer: biology chaos and treatment paradox.","volume":"41","author":"Yu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"zoi230131r43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.588080","article-title":"Case report: significant response to immune checkpoint inhibitor camrelizumab in a heavily pretreated advanced ER+\/HER2- breast cancer patient with high tumor mutational burden.","volume":"10","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"zoi230131r44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.v12i5","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer.","volume":"12","author":"O\u2019Meara","year":"2021","journal-title":"Oncotarget"},{"issue":"2","key":"zoi230131r45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-019-05173-4","article-title":"Loss of HER2 after HER2-targeted treatment.","volume":"175","author":"Ignatov","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"zoi230131r46","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"zoi230131r47","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/1078-0432.CCR-15-1488","article-title":"Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer, and prognostic implications in residual disease.","volume":"22","author":"Klintman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"zoi230131r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100794","article-title":"Modulation of mutational landscape in HER2-positive breast cancer after neoadjuvant chemotherapy.","volume":"13","author":"Omarini","year":"2020","journal-title":"Transl Oncol"},{"issue":"2","key":"zoi230131r49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"zoi230131r50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease.","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2802897\/zhao_2023_oi_230131_1679406279.72266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T11:44:48Z","timestamp":1680435888000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2802897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.3329","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}